Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA, it added.

Alembic Pharmaceuticals stated that it gained final FDA approval for the Diltiazem Hydrochloride Extended-Release capsules, which are used to treat hypertension.

These capsules will be available in dosages of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, offering a generic alternative to the brand-name Cardizem CD capsules marketed by Bausch Health in the United States,

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Diltiazem Hydrochloride extended-release capsules indicated for the treatment of hypertension.

Alembic Pharmaceuticals receives USFDA approval for generic Diltiazem Hydrochloride Capsules, boosting market presence and stock value.